ABSTRACT
Neuropathological studies are crucial for the new knowledge on pathophysiology and treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The postmortem brain tissue processing method directly impacts on both the appropriate integrity and the biomolecules detection by different histological and molecular biology techniques. In this review we will discuss topics on the influence of some external factors on the preservation of the brain tissue for histological studies (histochemistry and immunohistochemistry), such as factors either prior or after the death, and the chosen method for the preservation of nervous tissue. By means of a specific example, we propose a strict record of various conditions involved in the method of preservation of nervous tissue, and its correlation with variables that measure the quality of the histological sample as markers of preservation of biological material for further studies.
Os estudos neuropatológicos são fundamentais para novas descobertas sobre a fisiopatologia e o tratamento de doenças neurodegenerativas, como a doença de Alzheimer e a doença de Parkinson. O modo como o encéfalo pós-morte é processado influencia diretamente na adequada integridade e na detecção de biomoléculas por diferentes técnicas histológicas e de biologia molecular. Nesta revisão, abordaremos tópicos sobre a influência de determinados fatores externos sobre a preservação do encéfalo para estudos histológicos (histoquímica e imuno-histoquímica), como as condições anteriores e posteriores ao óbito, e o método escolhido de conservação do tecido nervoso. Por meio de um exemplo específico, propomos um rigoroso registro das diversas condições envolvidas no processo de preservação do tecido nervoso e sua correlação com variáveis que avaliam a qualidade da amostra histológica, como marcadores da preservação do material biológico para estudos posteriores..
ABSTRACT
OBJECTIVE: Scarce data are available on the occurrence of symptomatic intracranial hemorrhage related to intravenous thrombolysis for acute stroke in South America. We aimed to address the frequency and clinical predictors of symptomatic intracranial hemorrhage after stroke thrombolysis at our tertiary emergency unit in Brazil. METHOD: We reviewed the clinical and radiological data of 117 consecutive acute ischemic stroke patients treated with intravenous thrombolysis in our hospital between May 2001 and April 2010. We compared our results with those of the Safe Implementation of Thrombolysis in Stroke registry. Univariate and multiple regression analyses were performed to identify factors associated with symptomatic intracranial transformation. RESULTS: In total, 113 cases from the initial sample were analyzed. The median National Institutes of Health Stroke Scale score was 16 (interquartile range: 10-20). The median onset-to-treatment time was 188 minutes (interquartile range: 155-227). There were seven symptomatic intracranial hemorrhages (6.2%; Safe Implementation of Thrombolysis in Stroke registry: 4.9%; p = 0.505). In the univariate analysis, current statin treatment and elevated National Institute of Health Stroke Scale scores were related to symptomatic intracranial hemorrhage. After the multivariate analysis, current statin treatment was the only factor independently associated with symptomatic intracranial hemorrhage. CONCLUSIONS: In this series of Brazilian patients with severe strokes treated with intravenous thrombolysis in a public university hospital at a late treatment window, we found no increase in the rate of symptomatic intracranial hemorrhage. Additional studies are necessary to clarify the possible association between statins and the risk of symptomatic intracranial hemorrhage after stroke thrombolysis.